These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32594504)

  • 21. Rapid opioid detoxification in Australia.
    Reece S
    Acad Emerg Med; 2002 Sep; 9(9):960-2. PubMed ID: 12208687
    [No Abstract]   [Full Text] [Related]  

  • 22. A morphine/naltrexone combination (Embeda) for pain.
    Med Lett Drugs Ther; 2010 Mar; 52(1334):22-3. PubMed ID: 20336033
    [No Abstract]   [Full Text] [Related]  

  • 23. Naltrexone: Not Just for Opioids Anymore.
    Sudakin D
    J Med Toxicol; 2016 Mar; 12(1):71-5. PubMed ID: 26546222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unplanned admissions to two Sydney public hospitals after naltrexone implants.
    Kozminsky MP
    Med J Aust; 2008 Oct; 189(8):469-70; author reply 470-1. PubMed ID: 19031547
    [No Abstract]   [Full Text] [Related]  

  • 25. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.
    Comer SD; Collins ED; Kleber HD; Nuwayser ES; Kerrigan JH; Fischman MW
    Psychopharmacology (Berl); 2002 Feb; 159(4):351-60. PubMed ID: 11823887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
    Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
    Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets.
    Hamilton RJ; Olmedo RE; Shah S; Hung OL; Howland MA; Perrone J; Nelson LS; Lewin NL; Hoffman RS
    Acad Emerg Med; 2002 Jan; 9(1):63-8. PubMed ID: 11772672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.
    Brooks AC; Comer SD; Sullivan MA; Bisaga A; Carpenter KM; Raby WM; Yu E; O'Brien CP; Nunes EV
    J Clin Psychiatry; 2010 Oct; 71(10):1371-8. PubMed ID: 20673549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
    Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D;
    Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to Degenhardt et al.: 'depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy'.
    Brewer C
    Drug Alcohol Rev; 2008 Jul; 27(4):447-8; author reply 448-9. PubMed ID: 18584398
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
    Webster LR; Brewer R; Wang C; Sekora D; Johnson FK; Morris D; Stauffer J
    J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
    Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
    N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone.
    Mannelli P; Swartz M; Wu LT
    Am J Addict; 2018 Sep; 27(6):471-476. PubMed ID: 30028058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mental health outcomes following naltrexone implant treatment for heroin-dependence.
    Ngo HT; Tait RJ; Arnold-Reed DE; Hulse GK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):605-12. PubMed ID: 17229510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challenge.
    O'Brien B; Cody C
    Eur J Emerg Med; 2006 Oct; 13(5):315-6. PubMed ID: 16969243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
    Badalamenti VC; Buckley JW; Smith ET
    J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Injectable extended-release naltrexone for opioid dependence.
    Woody GE; Metzger DS
    Lancet; 2011 Aug; 378(9792):664-5; author reply 666. PubMed ID: 21856476
    [No Abstract]   [Full Text] [Related]  

  • 38. Advances in opioid antagonist treatment for opioid addiction.
    Ling W; Mooney L; Wu LT
    Psychiatr Clin North Am; 2012 Jun; 35(2):297-308. PubMed ID: 22640757
    [No Abstract]   [Full Text] [Related]  

  • 39. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy.
    Degenhardt L; Gibson A; Mattick RP; Hall W
    Drug Alcohol Rev; 2008 Jan; 27(1):1-3. PubMed ID: 18034375
    [No Abstract]   [Full Text] [Related]  

  • 40. Advantages of EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release capsules in pain management.
    Kapoor S
    J Opioid Manag; 2012; 8(4):207. PubMed ID: 22941847
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.